BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
BetterLife Pharma Inc. has announced the publication of an article on its lead candidate BETR-001 (2-bromo-LSD), highlighting its potential for treating depression without hallucinations. The article, featured in Drug Discovery & Development, elaborates on BETR-001's positive preclinical data and safety profile compared to LSD, developed in partnership with notable scientists. The company is advancing BETR-001 towards human clinical trials post-IND-enabling studies. BetterLife also develops other compounds for neuro-psychiatric and neurological disorders, including BETR-002. The management emphasizes the significant therapeutic potential of BETR-001 in neuro-psychiatric conditions.
- Publication of a positive article on BETR-001 in a reputable journal enhances visibility.
- BETR-001 demonstrates a favorable safety profile compared to traditional LSD.
- Company is progressing towards human clinical trials for BETR-001.
- None.
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, an article titled “Non-hallucinogenic LSD derivative reduces depression symptoms in preclinical studies,” based on BetterLife’s lead candidate BETR-001 (2-bromo-LSD) was published by Drug Discovery & Development on March 22, 2023.
The Drug Discovery & Development article describes and adds further comments to the positive data and extensive pharmacological characterization of BETR-001 which were published recently in the peer-reviewed journal Cell Reports. These studies were performed by BetterLife in collaboration with several leading scientists in this field: Dr. Adam L. Halberstadt (University of California San Diego, USA), Dr. Argel Aguilar-Valles (Carleton University, Canada), and Dr. John D. McCorvy (Medical College of Wisconsin, USA).
Ahmad Doroudian, CEO of BetterLife said, “As highlighted in this article, BetterLife’s proprietary BETR-001 (patent pending) has significant therapeutic potential in neuro-psychiatric disorders. Importantly, BETR-001 has an improved safety profile compared with LSD.” He added, “We are progressing with our BETR-001 IND-enabling studies and project to begin BETR-001 human clinical trials following the completion of the IND-enabling studies.”
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.
For further information, please visit BetterLife Pharma.
BetterLife Pharma Inc. Contact Information
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Cautionary Note Regarding Forward-Looking Statements
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What recent publication highlights BetterLife Pharma's BETR-001?
What is the significance of BETR-001 in mental health treatment?
When does BetterLife Pharma plan to begin human clinical trials for BETR-001?
What distinguishes BETR-001 from traditional LSD?
